FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
PMA: P240010
·
Supplement: S001
·
Decision Feb 6, 2025
Classifications
1
FEI Numbers
12
Registration Numbers
12
Basic Information
- Device Name
- Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
- Trade Name
- MI Cancer Seek
- PMA Number
- P240010
- Supplement Number
- S001
- Device Class
- FDA Class 3
- Product Code
- PQP
- Generic Name
- Next generation sequencing oncology panel, somatic or germline variant detection system
- Medical Specialty
- Unknown
- Advisory Committee
- Medical Genetics
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- February 6, 2025
- Date Received
- November 8, 2024
- Supplement Type
- Real-Time Process
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for a predetermined change control plan (PCCP) that includes minor software modifications consistent with the intended use of the assay and qualification of serial number-controlled instrument changes.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| PQP | Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System | FDA class 3 | Unknown |